Skip to Content

'
Charles A. Koller, M.D.

Present Title & Affiliation

Primary Appointment

Professor of Medicine, Internist,, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1973 Ohio State University, Columbus, OH, MD, Doctor of Medicine
1969 University of Michigan, Ann Arbor, MI, BA, BA

Postgraduate Training

1977-1978 Research Fellowship, Hematology/Oncology, Ohio State University, Columbus, OH
1976-1977 Clinical Fellowship, Hematology/Oncology, Ohio State University, Columbus, OH
1973-1976 Clinical Internship, Internal Medicine, University of North Carolina, Chapel Hill, NC
1973-1976 Clinical Residency, Internal Medicine, University of North Carolina, Chapel Hill, NC

Board Certifications

1980 Hematology
1979 Medical Oncology
1976 American Board of Internal Medicine

Experience/Service

Academic Appointments

Regular Member, Biomedical Sciences, The University of Texas Health Science Center at Houston, Houston, TX, 2/2008-present
Adjunct Professor, School of Health Sciences, The University of Texas MD Anderson Cancer Center School of Health Sciences, Houston, TX, 2002-present
Associate Professor of Medicine, Associate Internist,, Department of Leukemia, Division of Medicine,, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1985-2000
Assistant Professor, Department of Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, 1978-1985

Administrative Appointments/Responsibilities

Leukemia Center Medical Director(Responsible for outpatient and inpatient administration and financial budgeting),, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Leukemia Center Medical, Houston, TX, 1999-2010
Supervisor of Physician Extenders (29 member group of APN/PA Physician Extenders, both inpatient and outpatient),, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 1999-2010
Leukemia Department Homepage Webmaster and Primary E-Mail Contact, The University of Texas MD Anderson Cancer Center, Houston, TX, 1996-present

Institutional Committee Activities

Member, Bone Marrow Aspiration Steering Committee, 1/2008-present
Member, Cytokines & Supportive Care Working Group, UTMD Anderson Cancer Center, Houston, Texas,, 2007
Member, Clinical Effectiveness Committee of the Medical Staff, UTMD Anderson Cancer Center, Houston, Texas, 2007
Lead Member, Anemia Workgroup, UTMD Anderson Cancer Center., 1/2006-2/2008
Member, Program Review-Leukemia Data & Clinical Leadership, UT MD Anderson Cancer Center, Houston, Texas,, 2006
Member, Planned Relocation of Protected Environment Task Force, UT MD Anderson Cancer Center, Houston, Texas,, 2006
Member, Clinical Faculty Review Committee, UT M.D. Anderson Cancer Center, Houston, Texas, 2004-2008
Member, Search Committee for General Internal Medicine, Ambulatory Treatment and Emergency Care, UT M.D. Anderson Cancer Center, Houston, Texas, 2004
Member, Credentials Committee of the Medical Staff, UT M.D. Anderson Cancer Center, Houston, Texas, 2002-2008
Member, Pharmacy and Therapeutics Subcommittee, UT M.D. Anderson Cancer Center, Houston, Texas, 2001-present
Member, Clinical Research Committee, UT M.D. Anderson Cancer Center, Houston, Texas, 1999-2001
Director, Leukemia Fast Track Improvement Program, UT M.D. Anderson Cancer Center, Houston, Texas, 1999
Member, Antibiotic Task Force, UT M.D. Anderson Cancer Center, Houston, Texas, 1/1998-2006
Member, Computer Based Patient Record Steering Committee, UT M.D. Anderson Cancer Center, 1997-1999
Member, Infection Control Subcommittee, UT M.D. Anderson Cancer Center, Houston, Texas, 1994-2001
Member, Ethics Committee, UT M.D. Anderson Cancer Center, 1994-1999
Member, Quality Improvement and Utilization Management Reviewer, Department of Leukemia, UT M.D. Anderson Cancer Center, 1994-1999
Member, Ad-Hoc Statewide Out of Hospital DNR Subcommittee, UT M.D. Anderson Cancer Center, Houston, Texas, 1994-1997
Member, Surveillance Committee, UT M.D. Anderson Cancer Center, Houston, Texas, 1994-1995
Member, Faculty Senate Ad-Hoc Committee on Search Policy, UT M.D. Anderson Cancer Center, Houston, Texas, 1993-1995
Member, Faculty Senate Ad Hoc Committee on Travel, UT M.D. Anderson Cancer Center, Houston, Texas, 1993-1995
Member, Faculty Senate Finance Committee, UT M.D. Anderson Cancer Center, Houston, Texas, 1992-present
Member, Faculty Senate, UT M.D. Anderson Cancer Center, Houston, Texas, 1992-1994
Member, Ad Hoc Committee for MD-PhD Program Evaluation, UT M.D. Anderson Cancer Center, Houston, Texas, 1992-1993
Member, Faculty Senate Achievement Awards Committee, UT M.D. Anderson Cancer Center, Houston, Texas, 1992-1993
Member, Leukemia Patient Education Committee, UT M.D. Anderson Cancer Center, Houston, Texas, 1989-1997
Member, Parenteral and Enteral Nutrition Steering Committee, University of Michigan Hospital, Ann Arbor, Michigan, 1983-1985
Member, Transfusion Committee, University of Michigan Medical Center, Ann Arbor, Michigan, 1983-1985
Member, Medicial Director, Hematology/Oncology In-Patient Care Committee, University Hospital, Ann Arbor, Michigan, 1978-1986
Member, Cancer Work Group, University of Michigan, Ann Arbor, Michigan, 1978-1985
Member, Southwest Oncology Group, 1978-1985
Assistant Professor of Medicine, Division of Hematology/Oncology, Department of Medicine, University of Michigan, Ann Arbor, Michigan, Division of Hematology/Oncology, 1978-1985

Honors and Awards

2009 2009 Dr. John J. Kenney Award, The Leukemia & Lymphoma Society of America
2008 2008 Gerald P. Bodey Award for Excellence in Education, The University of Texas MD Anderson Cancer Center
2002 Platinum Award for Highest Fund Raiser each year, 2002 - 2009, HPD Bicycle Relay Team

Selected Publications

Peer-Reviewed Original Research Articles
1. Ravandi F, O'Brien S, Jorgensen J, Pierce S, Faderl S, Ferrajoli A, Koller C, Challagundla P, York S, Brandt M, Luthra R, Burger J, Thomas D, Keating M, Kantarjian H. Phase II study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood 118(14):3818-23, 10/2011. e-Pub 8/2011. PMID: 21821712.
2. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG. Cyclophosphamide, fludarabine, rituximab and alemtuzumab (CFAR) as salvage therapy for heavily pre-treated patients with chronic lymphocytic leukemia. Blood 118(8):2085-93, 8/2011. e-Pub 6/2011. PMID: 21670470.
3. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG. Fludarabine, cyclophosphamide and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 117(11):3016-24, 3/2011. e-Pub 1/2011. PMID: 21245487.
4. Cortes J, Quintás-Cardama A, Jones D, Ravandi F, Garcia-Manero G, Verstovsek S, Koller C, Hiteshew J, Shan J, O'Brien S, Kantarjian H. Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor. Cancer 117(3):572-80, 2/2011. e-Pub 9/2010. PMID: 20886606.
5. Mattiuzzi GN, Cortes J, Alvarado G, Verstovsek S, Koller C, Pierce S, Blamble D, Faderl S, Xiao L, Hernandez M, Kantarjian H. Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Support Care Cancer 19(1):19-26, 1/2011. e-Pub 12/2009. PMID: 19956980.
6. Carter BZ, Qiu YH, Zhang N, Coombes KR, Mak DH, Thomas DA, Ravandi F, Kantarjian HM, Koller C, Andreeff M, Kornblau SM. Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AML. Blood 117(3):780-7, 1/2011. e-Pub 11/2010. PMCID: PMC3035072.
7. Greenberg PL, Koller CA, Cabantchik ZI, Warsi G, Glynos T, Paley C, Schiffer C. Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes. Leuk Res 34(12):1560-5, 12/2010. e-Pub 7/2010. PMID: 20615548.
8. Ravandi F, Kantarjian H, Faderl S, Garcia-Manero G, O'Brien S, Koller C, Pierce S, Brandt M, Kennedy D, Cortes J, Beran M. Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. Leuk Res 34(6):752-6, 6/2010. e-Pub 10/2009. PMID: 19878996.
9. Verma D, Kantarjian H, Shan J, O'Brien S, Estrov Z, Garcia-Manero G, Koller C, Borthakur G, Cortes J. Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer 116(11):2673-81, 6/2010. PMID: 20499401.
10. Chen K, Puana RB, Price KJ, Koller CA, Nates JL. The Role of Point-of-Care Testing in the Early Diagnosis of Pseudo-Hypoxemia in Myeloproliferative Disorders. Respir Care 55(6):777-9, 6/2010. PMID: 20507664.
11. Han XY, Hellerstedt BA, Koller CA. Postsplenectomy Cytomegalovirus Mononucleosis is a Distinct Clinicopathologic Syndrome. Am J Med Sci 339(4):395-9, 4/2010. e-Pub 2/2010. PMID: 20195147.
12. Al Ameri A, Koller C, Kantarjian H, Ravandi F, Verstovsek S, Borthakur G, Pierce S, Mattiuzzi G. Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high-risk myelodysplastic syndrome. Cancer 116(1):93-7, 1/2010. e-Pub 10/2009. PMID: 19862814.
13. Cortes JE, Jones D, O'Brien S, Jabbour E, Ravandi F, Koller C, Borthakur G, Walker B, Zhao W, Shan J, Kantarjian H. Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia. J Clin Oncol 28((3)):398-404, 1/2010. e-Pub 12/2009. PMCID: PMC2815702.
14. Santos FP, Faderl S, Garcia-Manero G, Koller C, Beran M, O'Brien S, Pierce S, Freireich EJ, Huang X, Borthakur G, Bueso-Ramos C, de Lima M, Keating M, Cortes J, Kantarjian H, Ravandi F. Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution. Leukemia 23(12):2275-80, 12/2009. e-Pub 9/2009. PMID: 19741728.
15. Jabbour E, Jones D, Kantarjian HM, O'Brien S, Tam C, Koller C, Burger JA, Borthakur G, Wierda WG, Cortes J. Long-term outcome of patients with chronic myeloid leukemia treated with second generation, tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood 114(10):2037-43, 9/2009. e-Pub 6/2009. PMID: 19567878.
16. Garg R, Faderl S, Garcia-Manero G, Cortes J, Koller C, Huang X, York S, Pierce S, Brandt M, Beran M, Borthakur G, Kantarjian H, Ravandi F. Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome. Leukemia 23(7):1297-302, 7/2009. e-Pub 2/2009. PMID: 19242494.
17. Thomas DA, O'Brien S, Jorgensen JL, Cortes J, Faderl S, Garcia-Manero G, Verstovsek S, Koller C, Pierce S, Huh Y, Wierda W, Keating MJ, Kantarjian HM. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood 113(25):6330-6337, 6/2009. e-Pub 8/2008. PMCID: PMC2943753.
18. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller C, Burger J, Lerner S, Kantarjian H, Keating M. Characteristics Associated With Important Clinical End Points in Patients With Chronic Lymphocytic Leukemia at Initial Treatment. J Clin Oncol 27(10):1637-43, 4/1/2009. e-Pub 2/17/2009. PMID: 19224852.
19. Verma D, O'Brien S, Thomas D, Faderl S, Koller C, Pierce S, Kebriaei P, Garcia-Manero G, Cortes J, Kantarjian H, Ravandi F. Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens. Cancer 115(1):101-106, 1/2009. PMID: 19090005.
20. Schimmer AD, O'Brien S, Kantarjian H, Brandwein J, Cheson BD, Minden MD, Yee K, Ravandi F, Giles F, Schuh A, Gupta V, Andreeff M, Koller C, Chang H, Kamel-Reid S, Berger M, Viallet J, Borthakur G. A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res. 14(24):8295-301, 2008 Dec 15, 12/2008. PMID: 19088047.
21. Aribi A, Kantarjian H, Koller C, Thomas D, Faderl S, Garcia-Manero G, Cortes J. The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer 113(6):1338-43, 9/2008. PMID: 18629842.
22. Safdar A, Rodriguez GH, Rueda AM, Wierda WG, Ferrajoli A, Musher DM, O'Brien S, Koller CA, Bodey GP, Keating MJ. Multiple-dose granulocyte-macrophage-colony-stimulating factor plus 23-valent polysaccharide pneumococcal vaccine in patients with chronic lymphocytic leukemia: a prospective, randomized trial of safety and immunogenicity. Cancer 113(2):383-387, 7/2008.
23. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, Faderl S, Koller C, Morris G, Rosner G, Loboda A, Fantin VR, Randolph SS, Hardwick JS, Reilly JF, Chen C, Ricker JL, Secrist JP, Richon VM, Frankel SR, Kantarjian HM. Phase I study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 111(3):1060-6, 2/2008. PMID: 17962510.
24. Tsimberidou AM, Kantarjian HM, Wen S, O'Brien S, Cortes J, Wierda WG, Koller C, Pierce S, Brandt M, Freireich EJ, Keating MJ, Estey EH. The Prognostic Significance of Serum {beta}2 Microglobulin Levels in Acute Myeloid Leukemia and Prognostic Scores Predicting Survival:Analysis of 1,180 Patients. Clin Cancer Res. 14(3):721-30, 2/2008. PMID: 18245532.
25. Jabbour E, Kantarjian HM, Koller C, Taher A. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. Cancer 112(5):1089-1095, 1/2008. PMID: 18186499.
26. Cortes J, Jabbour E, Daley GQ, O'Brien S, Verstovsek S, Ferrajoli A, Koller C, Zhu Y, Statkevich P, Kantarjian H. Phase I study of lonafarnib (SCH66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib. Cancer 110(6):1295-302, 9/2007.
27. Ariba A, Kantarjian H, Koller C, Thomas D, Faderl S, Garcia-Manero G, Cortes J. The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer 113(6):1338-1343, 09/15/2008, 9/2007. PMID: 18629842.
28. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Cortes J, Thomas D, Garcia-Manero G, Koller C, Beran M, Giles F, Ravandi F, Lerner S, Kantarjian H, Keating M. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 109(11):4679-4685, 6/2007.
29. Aribi A, Kantarjian HM, Estey EH, Koller CA, Thomas DA, Kornblau SM, Faderl SH, Laddie NM, Garcia-Manero G, Cortes JE. Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. Cancer 109(7):1355-1359, 4/2007. PMID: 17326049.
30. Montero AJ, Estrov Z, Freireich EJ, Khouri IF, Koller CA, Kurzrock R. Phase II study of low dose interkeukin-11 in patients with myelodysplastic syndrome. Leukemia & Lymphoma 47(10):2049-2054, 10/2006.
31. Tsimberidou AM, O'Brien S, Kantarjian HM, Koller C, Hagemeister FB, Fayad L, Lerner S, Bueso-Ramos CE, Keating MJ. Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience. Cancer 107:1294-1302, 8/2006. PMID: 16902984.
32. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Wierda WG, Ravandi F, Koller C, Xiao L, Faderl S, Estrov Z, Cortes J, O'Brien S, Estey E, Bueso-Ramos C, Fiorentino J, Jabbour E, Issa JP. Phase I/II study of the combination of 5-aza-2' -deoxycytidine with valproic acid in patients with leukemia. Blood 108(10):3271-3279, 8/2006. PMID: 16882711.
33. Koller C, Bekele BN, Zhou X, Park C, Estrov Z, O'Brien S, Keating M, Jilani I, Giles FJ, Kantarjian HM, Albitar M. Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia. Blood 108(3):1001-6, 8/2006. PMID: 16551975.
34. Faderl S, Verstovsek S, Cortes J, Ravandi F, Beran M, Garcia-Manero G, Ferrajoli A, Estrov Z, O'Brien S, Koller C, Giles FJ, Wierda W, Kwari M, Kantarjian HM. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood 108(1):45-51, 7/2006. PMID: 16403905.
35. Argeles PC, Weiss PM, Koller CA, Kimmel S, Hess LW. Electronic residency application service scores: do they correlate with the rank order list for the match? J Reprod Med 51:471-4, 6/2006. PMID: 16846085.
36. Ravandi F, Jorgensen JL, O'Brien SM, Verstovsek S, Koller CA, Faderl S, Giles FJ, Ferrajoli A, Wierda WG, Odinga S, Huang X, Thomas DA, Freireich EJ, Jones D, Keating MJ, Kantarjian HM. Eradication of minimal residual disease in hairy cell leukemia. Blood 107(12):4658-4662, 6/2006. PMID: 16497968.
37. Ault P, Kantarjian H, O'Brien S, Faderl S, Beran M, Rios MB, Koller C, Giles F, Keating M, Talpaz M, Cortes J. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol 24(7):1204-1208, 3/2006. PMID: 16446320.
38. Oki Y, Kantarjian HM, Zhou X, Cortes J, Faderl S, Verstovsek S, O'Brien S, Koller C, Beran M, Bekele BN, Pierce S, Thomas D, Ravandi F, Wierda WG, Giles F, Ferrajoli A, Jabbour E, Keating MJ, Bueso-Ramos CE, Estey E, Garcia-Manero G. Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. Blood 107(3):880-884, 2/2006. PMID: 16123215.
39. Ravandi F, O'Brien S, Jones D, Lerner S, Faderl S, Ferrajoli A, Wierda W, Garcia-Manero G, Thomas D, Koller C, Verstovsek S, Giles F, Cortes J, Herling M, Kantarjian H, Keating M. T-cell prolymphocytic leukemia: a single-institution experience. Clin Lymphoma Myeloma 6(3):234-239, 11/2005. PMID: 16354329.
40. Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, Do KA, Cortes J, Koller C, Beran M, Ferrajoli A, Giles F, Lerner S, Albitar M, Kantarjian H, Keating M. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 23(18):4070-4078, 6/2005. PMID: 15767647.
41. Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D, Koller C, Wierda W, Detry MA, Lynn A, Kantarjian H. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23(18):4079-4088, 6/2005. PMID: 15767648.
42. Cortes J, Faderl S, Estey E, Kurzrock R, Thomas D, Beran M, Garcia-Manero G, Ferrajoli A, Giles F, Koller C, O'Brien S, Wright J, Bai SA, Kantarjian H. Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes. J Clin Oncol 23(12):2805-2812, 4/2005. PMID: 15728224.
43. Estey E, Koller C, Tsimberidou AM, O'Brien S, Beran M, Cortes J, Tirado-Gomez M, Lopez-Berestein G, Kantarjian H. Potential curability of newly diagnosed acute promyelocytic leukemia without use of chemotherapy: the example of liposomal all-trans retinoic acid. Blood 105(3):1366-7, 2/2005. PMID: 15659618.
44. Kantarjian H, Thomas D, O'Brien S, Cortes J, Giles F, Jeha S, Bueso-Ramos CE, Pierce S, Shan J, Koller C, Beran M, Keating M, Freireich EJ. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 101(12):2788-801, 12/2004. PMID: 15481055.
45. Sun X, Amin HM, Freireich EJ, Keating MJ, Kantarjian HM, Koller CA, O'Brien SM, Giles F, Albitar M. Hairy cell leukemia with large cells: long disease course with adequate response to therapy. Leukemia 18(11):1912-1914, 11/2004. PMID: 15385931.
46. Thomas DA, O'Brien S, Cortes J, Giles FJ, Faderl S, Verstovsek S, Ferrajoli A, Koller C, Beran M, Pierce S, Ha CS, Cabanillas F, Keating MJ, Kantarjian H. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood 104(6):1624-1630, 9/2004. PMID: 15178574.
47. Giles F, Thomas D, Garcia-Manero G, Faderl S, Cortes J, Verstovsek S, Ferrajoli A, Jeha S, Beran M, Koller C, Andreeff M, Cahill A, Clairmont C, Sznol M, Kantarjian H. A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia. Clin Cancer Res 10(9):2908-2917, 5/2004. PMID: 15131024.
48. Cortes J, Thomas D, Koller C, Giles F, Estey E, Faderl S, Garcia-Manero G, McConkey D, Ruiz SL, Guerciolini R, Wright J, Kantarjian H. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res 10(10):3371-3376, 5/2004. PMID: 15161691.
49. Sanders KE, Ha CS, Cortes-Franco JE, Koller CA, Kantarjian HM, Cox JD. The role of craniospinal irradiation in adults with a central nervous system recurrence of leukemia. Cancer 100(10):2176-2180, 5/2004. PMID: 15139061.
50. O'Brien SM, Kantarjian HM, Thomas DA, Cortes J, Giles FJ, Wierda WG, Koller CA, Ferrajoli A, Browning M, Lerner S, Albitar M, Keating MJ. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 98(12):2657-2663, 12/2003. PMID: 14669286.
51. Cortes J, Ault P, Koller C, Thomas D, Ferrajoli A, Wierda W, Rios MB, Letvak L, Kaled ES, Kantarjian H. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood 101(12):4714-4716, 6/2003. PMID: 12595304.
52. Thomas MB, Koller C, Yang Y, Shen Y, O'Brien S, Kantarjian H, Davis J, Estey E. Comparison of fludarabine-containing salvage chemotherapy regimens for relapsed/refractory acute myelogenous leukemia. Leukemia 17(5):990-993, 5/2003. PMID: 12750721.
53. Faderl S, Thomas DA, O'Brien S, Garcia-Manero G, Kantarjian HM, Giles FJ, Koller C, Ferrajoli A, Verstovsek S, Pro B, Andreeff M, Beran M, Cortes J, Wierda W, Tran N, Keating MJ. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 101(9):3413-3415, 5/2003. PMID: 12522009.
54. Cortes J, Kantarjian H, Albitar M, Thomas D, Faderl S, Koller C, Garcia-Manero G, Giles F, Andreeff M, O'Brien S, Keating M, Estey E. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome. Cancer 97(5):1234-1241, 3/2003. PMID: 12599230.
55. Cortes J, Albitar M, Thomas D, Giles F, Kurzrock R, Thibault A, Rackoff W, Koller C, O'Brien S, Garcia-Manero G, Talpaz M, Kantarjian H. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 101(5):1692-1697, 3/2003. PMID: 12411300.
56. Giles FJ, Faderl S, Thomas DA, Cortes JE, Garcia-Manero G, Douer D, Levine AM, Koller CA, Jeha SS, O'Brien SM, Estey EH, Kantarjian HM. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. J Clin Oncol 21(6):1050-1056, 3/2003. PMID: 12637470.
57. Mattiuzzi GN, Estey E, Raad I, Giles F, Cortes J, Shen Y, Kontoyiannis D, Koller C, Munsell M, Beran M, Kantarjian H. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. Cancer 97(2):450-456, 1/2003. PMID: 12518369.
58. Oosterveld M, Muus P, Suciu S, Koller C, Verhoef G, Labar B, Wijermans P, Aul C, Fiere D, Selleslag D, Willemze R, Gratwohl A, Ferrant A, Mandelli F, Cortes J, de Witte T, Estey E, EORTC, EBMT, SAKK, GIMEMA Leukemia Groups and the MD Anderson Cancer Center.. Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors. Leukemia 16(9):1615-21, 9/2002. PMID: 12200672.
59. Ault P, Cortes J, Koller C, Kaled ES, Kantarjian H. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res 26(9):881-884, 9/2002. PMID: 12127565.
60. Keating MJ, O'Brien S, Kontoyiannis D, Plunkett W, Koller C, Beran M, Lerner S, Kantarjian H. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 43(9):1755-1762, 9/2002. PMID: 12685828.
61. Ferrajoli A, Keating MJ, Manshouri T, Giles FJ, Dey A, Estrov Z, Koller CA, Kurzrock R, Thomas DA, Faderl S, Lerner S, O'Brien S, Albitar M. The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood 100(4):1215-1219, 8/2002. PMID: 12149200.
62. Kantarjian HM, Talpaz M, O'Brien S, Smith TL, Giles FJ, Faderl S, Thomas DA, Garcia-Manero G, Issa JP, Andreeff M, Kornblau SM, Koller C, Beran M, Keating M, Rios MB, Shan J, Resta D, Capdeville R, Hayes K, Albitar M, Freireich EJ, Cortes JE. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res 8(7):2177-2187, 7/2002. PMID: 12114418.
63. O'Brien S, Talpaz M, Cortes J, Shan J, Giles FJ, Faderl S, Thomas D, Garcia-Manero G, Mallard S, Beth M, Koller C, Kornblau S, Andreeff M, Murgo A, Keating M, Kantarjian HM. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. Cancer 94(7):2024-2032, 4/2002. PMID: 11932905.
64. Cortes J, Thomas D, Rios A, Koller C, O'Brien S, Jeha S, Faderl S, Kantarjian H. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 94(5):1492-1499, 3/2002. PMID: 11920506.
65. Surapaneni UR, Cortes JE, Thomas D, O'Brien S, Giles FJ, Koller C, Faderl S, Kantarjian H. Central nervous system relapse in adults with acute lymphoblastic leukemia. Cancer 94(3):773-779, 2/2002. PMID: 11857312.
66. Cortes J, O'Brien S, Loscertales J, Kantarjian H, Giles F, Thomas D, Koller C, Keating M. Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia. Cancer 92(8):2016-2022, 10/2001. PMID: 11596014.
67. Beran M, Shen Y, Kantarjian H, O'Brien S, Giles F, Koller C, Keating M, Kantarjian H. High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens. Cancer 92(8):1999-2015, 10/2001.
68. Aboul-Nasr R, O'Brien S, Freireich EJ, Ginsberg CF, Kantarjian HM, Koller CA, Keating MJ, Albitar M. "T-cell-rich B-cell lymphoproliferative disorder" of the bone marrow. Leuk Lymphoma 42(5):1023-1031, 9/2001. PMID: 11697619.
69. Verstovsek S, Kantarjian H, Estey E, Aguayo A, Giles FJ, Manshouri T, Koller C, Estrov Z, Freireich E, Keating M, Albitar M. Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome. Leukemia 15(8):1165-1170, 8/2001. PMID: 11480557.

Abstracts
1. Kiran Naqvi, MD*, Farhad Ravandi, MD, Hagop Kantarjian, MD, Gautam Borthakur, MD, Alessandra Ferrajoli, MD, Deborah A Thomas, MD, Charles Asa Koller, Marina Konopleva, MD, PhD, Anna Byrd, RN*, Monica Kwari, BSN and Stefan Faderl, MD. Phase II Study of the Combination of Clofarabine Plus Idarubicin and Cytarabine (CIA) In Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML). Blood (Ash Annual Meeting Abstracts) 116(1061) (#1061), 10/2010.
2. Farhad Ravandi, M.D., Jorge Cortes, MD, Stefan Faderl, MD, Susan O'Brien, MD, Guillermo Garcia-Manero, MD, Srdan Verstovsek, MD, PhD, Marcos de Lima, MD, Sherry Pierce, RN, Mark Brandt, Gautam Borthakur, MD, Alessandra Ferrajoli, MD, William G. Wierda, M.D., Ph.D, Charles A Koller, MD and Hagop M. Kantarjian, MD. Characteristics and Outcome of Patients with Acute Myeloid Leukemia (AML) Refractory to One Cycle of High Dose Cytarabine-Based Induction Chemotherapy. Blood (ASH Annual Meeting Abstracts) 114(22):430 (#1038), 11/2009.
3. Deborah A. Thomas, MD, Hagop M. Kantarjian, MD, Stefan Faderl, MD, William G. Wierda, MD, PhD, Jorge Cortes, MD, Jan A. Burger, MD, PhD1, Alessandra Ferrajoli, MD, Zeev Estrov, MD, Charles Koller, MD, Marina Konopleva, MD, PhD, Gautam Borthakur, MD, Elias Jabbour, MD, Farhad Ravandi, MD, Tapan Kadia, MD, Guillermo Garcia-Manero, MD, Steven M. Kornblau, MD, Michael Andreeff, MD, PhD, Rebecca Garris, Michael J. Keating, MDBS and Susan O'Brien, MD. Chemoimmunotherapy with a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome for Patients with De Novo Philadelphia Negative Precursor B-Cell Acute Lymphoblastic Leukemia (ALL). Blood (ASH Annual Meeting Abstracts) 114(22):344-345 (#836), 11/2009.
4. Tapan Kadia, MD, Steven M. Kornblau, MD, Hagop Kantarjian, MD, Stefan Faderl, MD, Dan Jones, MD, PhD, Guillermo Garcia-Manero, MD, Gautam Borthakur, Charles Koller, MD, Srdan Verstovsek, MD, PhD, Sherry Pierce, RN, Jorge Cortes, MD and Farhad Ravandi, MD. Clinical Characterization and Proteomic Consequences of Mutated Ras in Acute Myeloid Leukemia. Blood (ASH Annual Meeting Abstracts) 114(22):139-140 (#330), 11/2009.
5. Farhad Ravandi, MD, Hagop M. Kantarjian, MD, Jorge Cortes, MD, Deborah A. Thomas, MD, Stefan Faderl, MD, Dan Jones, MD, PhD, Elias Jabbour, MD, Charles Koller, MD, Samuel Dara, Rebecca Garris, Partow Kebriaei, MD, Gautam Borthakur, MD, Alessandra Ferrajoli, MD and Susan O'Brien. Combination of the Hypercvad Regimen with Dasatinib Is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB). Blood (ASH Annual Meeting Abstracts) 114(22):806-807 (#2043), 11/2009.
6. Jorge Cortes, Gautam Borthakur, Susan O'Brien, M.D., Dan Jones, Elias Jabbour, Farhad Ravandi, MD, Charles Koller, Brenda Walker, Jenny Shan and Hagop Kantarjian. Efficacy of Dasatinib in Patients (pts) with Previously Untreated Chronic Myelogenous Leukemia (CML) in Early Chronic Phase (CML-CP). Blood (ASH Annual Meeting Abstracts) 114(22):143 (#338), 11/2009.
7. Sameer A Parikh, MD, Michael Keating, MD, Susan O'Brien, Alessandra Ferrajoli, Stefan Faderl, MD, Charles Koller, MD, Zeev Estrov, Susan Lerner, M.S., RHIA and William G. Wierda, M.D., Ph.D. Frontline Combined Chemoimmunotherapy with Fludarabine, Cyclophosphamide, Alemtuzumab and Rituximab (CFAR) in High-Risk Chronic Lymphocytic Leukemia. Blood (ASH Annual Meeting Abstracts) 114(22):91-92 (#208), 11/2009.
8. Tapan Kadia, MD, Zeev Estrov, MD, Farhad Ravandi, M.D., Charles Asa Koller, MD, Gautam Borthakur, MD*, Elias Jabbour, MD, Stefan Faderl, MD, Sherry Pierce, RN*, Jorge Cortes, MD, Hagop M. Kantarjian, MD and Guillermo Garcia-Manero, MD. Long Term Followup and Patterns of Failure in Patients with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Treated On Studies Combining a Hypomethylating Agent and the Histone Deacetylase Inhibitor (HDACi) Valproic Acid. Blood (ASH Annual Meeting Abstracts) 114(22):818-819 (#2074), 11/2009.
9. Farhad Ravandi, MD, Hagop M. Kantarjian, MD, Deborah A. Thomas, MD, Stefan Faderl, MD, Dan Jones, MD, PhD, Charles A Koller, MD, Samuel Dara, Rebecca Garris, Partow Kebriaei, MD, Richard Champlin, MD, Gautam Borthakur, MD, William G. Wierda, M.D., Ph.D, Jan A. Burger, MD, PhD, Jorge Cortes, MD and Susan O'Brien. Phase II Study of Combination of the Hypercvad Regimen with Dasatinib in the Front Line Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL). Blood (ASH Annual Meeting Abstracts) 114(22):345 (#837), 11/2009.
10. Fabio P.S. Santos, Stefan Faderl, Guillermo Garcia-Manero, Charles A. Koller, Miloslav Beran, Gautam Borthakur, Carlos Bueso-Ramos, Michael Keating, Jorge Cortes, Hagop M. Kantarjian, and Farhad Ravandi. Acute Erythroleukemia: An Analysis of 108 Patients Treated with Cytarabine-Containing Regimens at the M.D. Anderson Cancer Center. Blood (ASH Annual Meeting Abstracts) 112 (#925), 11/2008.
11. Ali M Alameri, Charles Asa Koller, Sherry Pierce, and Gloria Mattiuzzi. Acute Pulmonary Hemorrhage in Patients with Acute Myeloid Leukemia (AML) during Remission Induction Chemotherapy. Blood (ASH Annual Meeting Abstracts) 112 (#4031), 11/2008.
12. William G Wierda, Susan M O’Brien, Stefan H Faderl, Alessandra Ferrajoli, Charles Koller, Zeev Estrov, Jan A Burger, Susan Lerner, Hagop M. Kantarjian, and Michael J Keating. CFAR, An Active Frontline Regimen for High-Risk Patients with CLL, Including Those with Del 17p. Blood (ASH Annual Meeting Abstracts), 112 (#2095), 11/2008.
13. Peter L Greenberg, Charles Schiffer, Charles A Koller, Tara Glynos, and Carole Paley. Change in Liver Iron Concentration (LIC), Serum Ferritin (SF) and Labile Plasma Iron (LPI) Over 1 Year of Deferasirox (DFX/Exjade®) Therapy in a Cohort of Myelodysplastic Patients. Blood (ASH Annual Meeting Abstracts) 112 (#5083), 11/2008.
14. Xavier C. Badoux, MBBS, Michael Keating, MD, Susan O'Brien, MD, Tapan Kadia, MD, Alessandra Ferrajoli, MD., Stefan Faderl, MD, Charles Koller, MD, Guillermo Garcia-Manero, MD, Jan A. Burger, MD, PhD and William G. Wierda, M.D., Ph.D. Chemoimmunotherapy with Cyclophosphomide, Fludarabine, Alemtuzumab and Rituximab (CFAR) Is Effective in Relapsed Patients with Chronic Lymphocytic Leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 114(22):1332-1333 (#3431), 11/2008.
15. Gautam Borthakur, Constantine Tam, Hagop Kantarjian, E. Lin, Jorge Cortes, Susan O’Brien, Charles Koller, Sherry Pierce, and Michael Keating. Chromosome 17 Abnormalities Are Associated with Worse Overall and Relapse Free Survival in Patients with Acute Myelogenous Leukemia. Blood (ASH Annual Meeting Abstracts), 112 (#1501), 11/2008.
16. Elias Jabbour, Susan O’Brien, Deborah A. Thomas, Stefan Faderl, Charles Asa Koller, Samuel Dara, Rebecca Garris, Jorge Cortes, Hagop M Kantarjian, and Farhad Ravandi. Combination of the hyperCVAD Regimen with Dasatinib Is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Meyloid Leukemia (CML-LB). Blood (ASH Annual Meeting Abstracts) 112 (#2919), 11/2008.
17. Jorge Cortes, Susan O’Brien, Gautam Borthakur, Dan Jones, Farhad Ravandi, Charles Koller, Ofelia Mesina, Alessandra Ferrajoli, Jianqin Shan, and Hagop Kantarjian. Efficacy of Dasatinib in Patients (pts) with Previously Untreated Chronic Myelogenous Leukemia (CML) in Early Chronic Phase (CML-CP). Blood (ASH Annual Meeting Abstracts), 112 (#182), 11/2008.
18. Stefan Faderl, Deborah A. Thomas, Charles A. Koller, Farhad Ravandi, Jan Burger, Susan O’Brien, Samuel Dara, and Hagop M. Kantarjian. Hyper-CVAD Plus Nelarabine: A Pilot Study for Patients with Newly Diagnosed T Cell Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LL). Blood (ASH Annual Meeting Abstracts), 112 (#3960), 11/2008.
19. Deborah A. Thomas, Hagop Kantarjian, Stefan Faderl, William G. Wierda, Alessandra Ferrajoli, Jan A. Burger, Jorge Cortes, Charles A. Koller, Gautam Borthakur, Zeev Estrov, Marina Konopleva, Farhad Ravandi, Guillermo Garcia- Manero, and Susan O’Brien. Outcome after Frontline Therapy with the Modified Hyper-CVAD Regimen with or without Rituximab for De Novo Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL). Blood (ASH Annual Meeting Abstracts) 112 (#1931), 11/2008.
20. Farhad Ravandi, Deborah Thomas, Hagop Kantarjian, Stefan Faderl, Charles Koller, Samuel Dara, Rebecca Garris, Partow Kebriaei, Gautam Borthakur, William Wierda, Jan Burger, Jorge Cortes, and Susan O’Brien. Phase II Study of Combination of hyperCVAD with Dasatinib in Frontline Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL). Blood (ASH Annual Meeting Abstracts) 112 (#2921), 11/2008.
21. RJ Garg, Guillermo Garcia-Manero, Stefan Faderl, Jorge Cortes, Charles Asa Koller, Miloslav Beran, Gautam Borthakur, Hagop M Kantarjian, and Farhad Ravandi. Phase II Study of Thymoglobulin, Cyclosporine and G-CSF for Initial Treatment of Aplastic Anemia and Low Risk Myelodysplastic Syndrome. Blood (ASH Annual Meeting Abstracts) 112 (#5080), 11/2008.
22. Stefan Faderl, Gautam Borthakur, Farhad Ravandi, Xuelin Huang, Miloslav Beran, Alessandra Ferrajoli, Charles A. Koller, Deborah A. Thomas, Srdan Verstovsek, Monica Kwari, and Hagop M. Kantarjian. Results of a Randomized Phase 2 Study of Clofarabine Plus Cytarabine (CA) Vs Clofarabine Plus Idarubicin (CI) Vs Clofarabine, Idarubicin, Plus Cytarabine (CIA) as Salvage Therapy in Acute Myeloid Leukemia (AML). Blood (ASH Annual Meeting Abstracts) 112 (#964), 11/2008.
23. G. Borthakur, H.M. Kantarjian, S.M. O'Brien, D. Jones, C. Koller, C. Nicaise, G. Garcia-Manero, A. Ferrajoli, J.E. Cortes. Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP). 2008 ASCO Annual Meeting (#7013), 5/2008.
24. R. J. Garg, N. Shah, G. Garcia-Manero, S. Stefan Faderl, J. E. Cortes, C. Koller, M. Beran, G. Borthakur, H. M. Kantarjian, F. Ravandi. Phase II study of thymoglobulin, cyclosporine and G-CSF for initial treatment of aplastic anemia and low risk myelodysplastic syndrome. 2008 ASCO Annual Meeting (#7093), 5/2008.
25. Apostolia-Maria Tsimberidou, Hagop Kantarjian, Susan O'Brien, Guillermo Garcia-Manero, Charles Koller, Daniel Jones, Sherry Pierce, Mark Brandt, Michael Keating, Estey Estey. All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (As2O3) Combination Therapy Induces High Rates of Durable Molecular Remission in Newly Diagnosed Acute Promyelocytic Leukemia (APL). ASH 49th Annual Meeting 2007 (#1834), 12/2007.
26. William G. Wierda, S. O'Brien, A. Ferrajoli, S. Faderl, C. Koller, Z. Estrov, G. Garcia-Manero, S. Verstovsek, M. Browning, S. Lerner, M. Keatin. Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Frontline Regimen for High-Risk Patients with CLL. 49th ASH Annual Meeting and Exposition (#628), 12/2007.
27. Jorge Cortes, Susan O'Brien, Dan Jones, Charles Koller, Gautam Borthakur, Claude Nicaise, Laverne Henderson, Alessandra Ferrajoli, Hagop Kantarjian. Efficacy of Dasatinib in Patients (pts) with Previously Untreated Chronic Myelogenous Leukemia (CML) in Early Chronic Phase (CML-CP). 49th ASH Annual Meeting and Exposition (#30), 12/2007.
28. Jorge Cortes, Susan O'Brien, Dan Jones, Charles Koller, Gautam Borthakur, Claude Nicaise, Laverne Henderson, Alessandra Ferrajoli, Hagop Kantarjian. Efficacy of Dasatinib in Patients (pts) with Previously Untreated Chronic Myelogenous Leukemia (CML) in Early Chronic Phase (CML-CP). 49th ASH Annual Meeting and Exposition (#30), 12/2007.
29. Elias Jabbour, Hagop Kantarjian, Dan Jones, Constantine Tam, Charles Koller, Gautam Borthakur, William Wierda, Jorge Cortes. Event-Free Survival in Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with 2nd Generation Tyrosine Kinase Inhibitors (TKI) after Imatinib Failure Is Dependent on the In Vitro Sensitivity of BCR-ABL Kinase Domain (KD) Mutations. 49th ASH Annual Meeting and Exposition (#1941), 12/2007.
30. John Delmonte, Jr., Hagop M. Kantarjian, Guillermo Garcia-Manero, Zeev Estrov, Farhad Ravandi, Srdan Verstovsek, Susan O'Brien, Charles A. Koller, Stefan Faderl, Deborah A. Thomas, John J. Wright, Jorge Cortes Leukemia. Final Update of Phase I-II Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome. 49th ASH Annual Meeting and Exposition (#441), 12/2007.
31. Stefan Faderl, Deborah A. Thomas, Farhad Ravandi, Guillermo Garcia-Manero, Miloslav Beran, Michael Rytting, Charles A. Koller, Srdan Verstovsek, Gautam Borthakur, Michael Andreeff, Steve Kornblau, Susan O'Brien, Khanh Vu, Monica Kwari, Jennie Bretz, Hagop M. Kantarjian. Intensification of Hyper-CVAD with L-Asparaginase, Vincristine, and Dexamethasone (Augmented Hyper-CVAD) Has Activity in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL). 49th ASH Annual Meeting and Exposition (#4324), 12/2007.
32. Farhad Ravandi, Stefan Faderl, Deborah Thomas, Jan Burger, Charles Koller, Guillermo Garcia-Manero, Gail Morris, Ritva Torma, Hagop Kantarjian, Jean-Pierre Issa. Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA) and Decitabine in Patients with Relapsed, Refractory or Poor Prognosis Leukemia. 49th ASH Annual Meeting and Exposition (#897), 12/2007.
33. Farhad Ravandi, Deborah Thomas, Hagop Kantarjian, Stefan Faderl, Charles Koller, Devri Brown, Rebecca Garris, Gautam Borthakur, Jan Burger, Partow Kebriaei, Jeffrey Jorgensen, Dan Jones, Jorge Cortes, Susan O'Brien. Phase II Study of Combination of the HyperCVAD Regimen with Dasatinib in Patients with Philadelphia Chromosome (Ph) or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB. 49th ASH Annual Meeting and Exposition (#2814), 12/2007.
34. Alfonso Quintás-Cardama, Hagop Kantarjian, Deborah Thomas, Charles Koller, Jenny Shan, Jorge Cortes. Prognostic Impact of Deletions of Derivative Chromosome 9 on Patients (pts) with Chronic Myelogenous Leukemia (CML) in Chronic Phase Treated with Nilotinib or Dasatinib. 49th ASH Annual Meeting and Exposition (#1955), 12/2007.
35. Gautam Borthakur, Hagop Kantarjian, Susan O'Brien, Farhad Ravandi, Charles Koller, Zeev Estrov, Ritva Torma, Jean-Pierre Issa. Report of a Phase1/2 Study of 5-Azacitidine and Cytarabine in Patients with Relapsed, Refractory Acute Myelogenous Leukemia. 49th ASH Annual Meeting and Exposition (#911), 12/2007.
36. Dushyant Verma, Hagop Kantarjian, Zeev Estrov, Guillermo Garcia-Manero, Charles Koller, Gautam Borthakur, Jorge Cortes. Survival Outcomes for Patients (Pts) with Chronic Myeloid Leukemia (CML) with Clonal Evolution (CE) Treated with 2nd Generation Tyrosine Kinase Inhibitors (TKI) after Imatinib Failure. 49th ASH Annual Meeting and Exposition (#2949), 12/2007.
37. Dushyant Verma, Deborah Thomas, Susan O'Brien, Stefan Faderl, Charles Koller, Sherry Pierce, Elihu Estey, Guillermo Garcia-Manero, Jorge Cortes, Hagop Kantarjian, Farhad Ravandi. Therapy Related Acute Myelogenous Leukemia and Myelodysplastic Syndrome in Patients with Acute Lymphoblastic Leukemia Treated with the Hyper-CVAD Regimen. 49th ASH Annual Meeting and Exposition (#2832), 12/2007.
38. Deborah A. Thomas, Hagop Kantarjian, Stefan Faderl, Charles Koller, Farhad Ravandi-Kashani, Miloslav Beran, Susan O'Br. Update of the Modified Hyper-CVAD Regimen with or without Rituximab as Frontline Therapy of Adults with Acute Lymphocytic Leukemia (ALL) or Lymphoblastic Lymphoma (LL. 49th ASH Annual Meeting and Exposition (#2824), 12/2007.
39. A. Aribi, H. Kantarjian, S. O'Brien, C. Koller, S. Verstovsek, S. Faderl, M. Keating, F. Ravandi-Kash. Combination therapy with alemtuzumab and pentostatin is effective and has acceptable toxicity in patients with T-lymphoid neoplasms. 2007 ASCO Annual Meeting Vol 25, No. 18S (#7037), 6/2007.
40. y. Alvarado, H. Kantarjian, E. J. Freireich, G. Garcia-Manero, A. Ferrajoli, C. Koller, Z. Estrov, S. Kornblau, N. Laddie, L. Smith, J. Cortes. Phase II dosing study of cytarabine chemotherapy in combination with cenersen (EL625) and idarubicin in refractory and relapsed acute myelogenous leukemia (AML). 2007 ASCO Annual Meeting Vol 25, No. 18S (#7070), 6/2007.
41. Safdar A, Rodriguez GH, Wierda WG, Musher DM, Rueda AM, O'Brien S, Koller CA, Bodey GP, Keating MJ. Immunogenicity and Safety of Multi-Dose Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Immune Enhancement in Patients with Chronic Lymphocytic Leukemia (CLL) Receiving 23-Valent Polysaccharide Pneumococcal Vaccine (PPV23):A Prospective Randomized Controlled Trial. 10th Annual Conference on Vaccine Research Sponsored by National Foundation for Infectious Diseases, Bethesda, MD., Baltimore, MD, April 30-May 2, 2007, Oral Presentation, 5/2007.
42. Garcia-Manero G, Issa JP, Cortes C, Koller C, O'Brien S, Estey E, Canalli AA, Chiao J, Richon V, Kantarjian H. Phase I study of oral suberoylanilide hydroxamic acid (SAHA), as histone Leukemia (CLL) Receiving 23-Valent Polysaccharide Pneumococcal Vaccine (PPV23): A Prospective, Randomized, Controlled Trial. 10th Annual Conference on Vaccine Research Sponsored by National Foundation for Infectious Diseases, Bethesda, MD. Baltimore, MD April 30-May 2:Oral Presentation, 2007.
43. Farhad Ravandi-Kashani, Hagop Kantarjian, Stefan Faderl, Srdan Verstovsek, Charles Koller, Shirley Odinga, William Wierda, Gautam Borthakur, Dan Jones, Francis Giles, Susan O’Brien, and Michael Keating. Combination Therapy with Alemtuzumab and Pentostatin Is Effective and Has Acceptable Toxicity in Patients with T-Lymphoid Neoplasms. 48th ASH Annual Meeting & Exhibition (#4971), 11/2006.
44. William G. Wierda, Susan O’Brien, Stefan Faderl, Alessandra Ferrajoli, Farhad Ravandi-Kashani, Jorge Cortes, Francis Giles, Michael Andreeff, Charles Asa Koller, Susan Lerner, Hagop M. Kantarjian, and Michael J. Keating. Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Regimen for Heavily Treated Patients with CLL. 48th ASH Annual Meeting & Exhibition (#31), 11/2006.
45. Ricardo H. Alvarez, Hagop Kantarjian, Guillermo Garcia-Manero, Zeev Estrov, Farhad Ravandi-Kashani, Srdan Verstovsek, Francis Giles, Susan O’Brien, Charles Asa Koller, Stefan Faderl, Deborah Thomas, John J. Wright, and Jorge Cortes. Farnesyl Transferase Inhibitor (Tipifarnib, Zarnestra; Z) in Combination with Standard Chemotherapy with Idarubicin (Ida) and Cytarabine (ara-C) for Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS). 48th ASH Annual Meeting & Exhibition (#1999), 11/2006.
46. Apostolia-Maria Tsimberidou, Michael J. Keating, Hagop M. Kantarjian, Susan O’Brien, Jorge Cortes, Charles Koller, Francis Giles, Sherry Pierce, Mark Brandt, Miloslav Beran, and Elihu Estey. Granulocytic Sarcoma (GS) Is Associated with Event-Free Survival Superior to That of Acute Myeloid Leukemia (AML). 48th ASH Annual Meeting & Exhibition (#2008), 11/2006.
47. Alfonso Quintas-Cardama, Hagop M. Kantarjian, Farhad Ravandi, Guillermo Garcia-Manero, Susan O’Brien, Srdan Verstovsek, Charles Asa Koller, Odeal Pate, and Jorge Cortes. Immune Modulation of Minimal Residual Disease (MRD) in Patients (pts) with Chronic Myelogenous Leukemia (CML) in Early Chronic Phase (CP): A Randomized Trial of Frontline High-Dose (HS) Imatinib Mesylate (IM) with or without Pegylated-Interferon (PEG-IFN) and GM-CSF. 48th ASH Annual Meeting & Exhibition (#2207), 11/2006.
48. Peter L. Greenberg, Charles A. Schiffer, Charles Asa Koller, Barinder Kang, Jodie Decker, and Carole Paley. Liver Iron Concentration Measurements Using MRI R2 in MDS Patients in a Deferasirox (Exjade®, ICL670) Phase II Study. 48th ASH Annual Meeting & Exhibition (#4846), 11/2006.
49. Deborah A. Thomas, Hagop M. Kantarjian, Jeffrey L. Jorgensen, Stefan Faderl, Jorge Cortes, Francis Giles, Guillermo Garcia-Manero, William Wierda, Alessandra Ferrajoli, Farhad Ravandi-Kashani, Charles Asa Koller, Miloslav Beran, Steven M. Kornblau, Michael Andreeff, Dan Jones, and Susan. Outcome after Detection of Minimal Residual Disease during Treatment with the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL). 48th ASH Annual Meeting & Exhibition (#1861), 11/2006.
50. Elias Jabbour, Hagop Kantarjian, Charles A. Koller, Stefan Faderl, Alessandra Ferrajoli, Mary Ann Richie, Guillermo Garcia-Manero, Jorge Cortes, Zeev Estrov, Farhad Ravandi-Kashani, Francis Giles, and Srdan Verstovsek. PEG-Intron Therapy in Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders (MPD): Final Result of a Phase II Study. 48th ASH Annual Meeting & Exhibition (#3636), 11/2006.
51. Farhad Ravandi-Kashani, Zeev Estrov, Alessandra Ferrajoli, Gautam Borthakur, Miloslav Beran, Sherry Pierce, Charles A. Koller, Jorge Cortes, Stefan Faderl, and Hagop M. Kantarjian. Phase II Study of Thymglobulin, Cyclosporin, and G-CSF for the Initial Treatment of Aplastic Anemia and Low Risk Myelodysplastic Syndrome. 48th ASH Annual Meeting & Exhibition (#4830), 11/2006.
52. Apostolia-Maria Tsimberidou, Hagop M. Kantarjian, Michael J. Keating, Susan O’Brien, Sijin Wen, Jorge Cortes, Francis Giles, Charles Asa Koller, Guillermo Garcia-Manero, Sherry Pierce, Mark Brandt, Emil J. Freireich, and. Prognostic Significance of ß-2 Microglobulin Levels in Acute Myeloid Leukemia: Analysis of 1293 Patients. 48th ASH Annual Meeting & Exhibition (#802), 11/2006.
53. Constantine S. Tam, Hagop M. Kantarjian, Jenny Shan, William G. Wierda, Alessandra Ferrajoli, Charles Asa Koller, and Jorge Cortes. Sokal and Hasford Scores Are Able To Predict Cytogenetic Response and Survival in CML Patients Who Failed Prior Therapy and Are Receiving Salvage Therapy with Imatinib or Other Tyrosine Kinase Inhibitors. 48th ASH Annual Meeting & Exhibition (#2157), 11/2006.
54. Ahmed M. Aribi, Hagop Kantarjian, Patricia Ault, Charles Asa Koller, Deborah Thomas, Stefan Faderl, Guillermo Garcia-Manero, and Jorge Cortes. The Effect of Interleukin-11 (Oprelvekin, Neumega®) on Thrombocytopenia Associated with Tyrosine Kinase Inhibitors (TKI) in Patients with Chronic Myeloid Leukemia (CML). 48th ASH Annual Meeting & Exhibition (#2148), 11/2006.
55. A. M. Tsimberidou, H. M. Kantarjian, G. Garcia-Manero, C. Koller, D. M. Jones, M. J. Keating, E. Estey. Clinical outcomes and rates of molecular remission with all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) combination therapy in newly diagnosed acute promyelocytic leuke. 2006 ASCO Annual Meeting Vol 24, No. 18S, 6/2006.
56. A. M. Aribi, H. Kantarjian, E. Estey, E. Freireich, C. Koller, D. Thomas, S. Kornblau, S. Faderl, N. Laddie, G. Garcia-Manero, J. Cortes. Combination therapy with arsenic trioxide (ATO), all-trans retinoic acid (ATRA), and gemtuzumab ozogamycin (GO) in relapsed acute promyelocytic leukemia (APL. 2006 ASCO Annual Meeting Vol 24, No. 18S (#6558), 6/2006.
57. A. O. Soriano, H. Yang, S. Verstovsek, W. Wierda, C. Koller, Z. Estrov, S. Ouzounian, H. Kantarjian, J. Issa, G. Garcia-Manero. Phase I/II study of the combination of 5-azacytidine(5-AC), all-trans retinoic acid (ATRA) and valproic Acid (VPA) in patients with myelodysplastic syndrome (MDS) and leukemia. 2006 ASCO Annual Meeting Vol 24, No. 1 (#6563), 6/2006.
58. S. Verstovsek, J. Cortes, D. Thomas, M. Beran, C. Koller, F. Giles, H. Kantarjian. Phase II study of lenalidomide (CC-5013) for patients with myelofibrosis. 2006 ASCO Annual Meeting Vol 24, No. 18S (#6510), 6/2006.

Books (edited and written)
1. Kantarjian H, Wolff R, Koller CA (Editors). Ed(s) Kantarjian H, Wolff R, Koller CA (Editors). MD Anderson Manual of Medical Oncology Second Edition, 2. McGraw-Hill Professional: Illinois, 2011. ISBN: 0071701060 / 9780071701068.
2. Kantarjian H, Wolff R, Koller CA (Editors). M.D. Anderson Manual of Medical Oncology., 1. McGraw-Hill: Illinois, 2006.

Last updated: 12/19/2012